Merck Group

Analytical Standards Market Worth $2.1 Billion | MarketsandMarkets

Retrieved on: 
Tuesday, October 17, 2023

The pharmaceutical & life sciences standards segment accounted for the largest share of analytical standards in 2023-2028.

Key Points: 
  • The pharmaceutical & life sciences standards segment accounted for the largest share of analytical standards in 2023-2028.
  • Based on application, the pharmaceutical & life sciences standards segment is estimated to hold the largest market share of the analytical standards market during the forecast period.
  • In 2023, Asia Pacific is expected to register the highest CAGR in the market for analytical standards during the forecast period.
  • Data Integrity: Analytical standards contribute to maintaining the integrity of scientific data, which is fundamental in decision-making processes, research, and policy development.

Analytical Standards Market Worth $2.1 Billion | MarketsandMarkets

Retrieved on: 
Tuesday, October 17, 2023

The pharmaceutical & life sciences standards segment accounted for the largest share of analytical standards in 2023-2028.

Key Points: 
  • The pharmaceutical & life sciences standards segment accounted for the largest share of analytical standards in 2023-2028.
  • Based on application, the pharmaceutical & life sciences standards segment is estimated to hold the largest market share of the analytical standards market during the forecast period.
  • In 2023, Asia Pacific is expected to register the highest CAGR in the market for analytical standards during the forecast period.
  • Data Integrity: Analytical standards contribute to maintaining the integrity of scientific data, which is fundamental in decision-making processes, research, and policy development.

Tessellate BIO Emerges from Stealth

Retrieved on: 
Tuesday, October 17, 2023

Its lead program targets the DNA damage response (DDR) and in particular cancers that depend on Alternative Lengthening of Telomeres (ALT).

Key Points: 
  • Its lead program targets the DNA damage response (DDR) and in particular cancers that depend on Alternative Lengthening of Telomeres (ALT).
  • The company aims to become a global leader in precision oncology by redefining Synthetic Lethality.
  • While Synthetic Lethality approaches targeting Homology Recombination Deficiency (HRD) have been successfully validated in the clinic by PARP inhibitors, there remains a vast and largely unexplored space in Synthetic Lethality beyond HRD that Tessellate BIO is pioneering.
  • I have been hugely impressed by the ambition at Tessellate BIO and by the progress already made towards the vision of impacting patient care – turning cancer patients into cancer survivors.”

EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023

Retrieved on: 
Monday, October 16, 2023

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.

Key Points: 
  • EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.
  • Additional presentations and activities at ESMO highlight the company’s efforts to improve the lives of people with cancer.
  • New analyses and real-world evidence to be presented at ESMO reinforce the role of the JAVELIN Bladder regimen in this setting.
  • In September 2023, the accelerated approval in the US was converted into full approval for use of BAVENCIO for the treatment of metastatic MCC.

Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS

Retrieved on: 
Wednesday, October 11, 2023

These data, presented at the 9th Joint ECTRIMS-ACTRIMS meeting, may indicate the long-term positive benefits of evobrutinib for people with RMS.

Key Points: 
  • These data, presented at the 9th Joint ECTRIMS-ACTRIMS meeting, may indicate the long-term positive benefits of evobrutinib for people with RMS.
  • During the OLE, patients were switched from evobrutinib 75 mg once-daily to 75 mg twice-daily resulting in additional ARR reduction.
  • Overall, treatment emergent adverse events (TEAEs) were mild/moderate in the OLE, with 3.3% (n=7) of patients with RMS experiencing a serious TEAE.
  • Collectively, the findings may indicate sustained benefit of long-term twice-daily dosing, and the safety profile remains consistent with that previously reported.

EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation

Retrieved on: 
Tuesday, October 10, 2023

These data were presented at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan, Italy.

Key Points: 
  • These data were presented at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan, Italy.
  • In a separate study out of Latin America, data was analyzed from 1,421 patients who received at least one course of cladribine tablets.
  • Over time, an increasing trend in treatment initiation among treatment-naïve patients was observed, suggesting an advantage of early utilization of cladribine treatment.
  • As well in both studies, very few patients receiving cladribine tablets switched to other therapies.

EMD Serono Launches New Collaboration with United Nations-Guided Global Initiative on Ageing to Support Caregivers

Retrieved on: 
Thursday, October 5, 2023

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced a new collaboration with the United Nations-Guided Global Initiative on Ageing (GIA) to provide a training course on critical skills for family caregivers.

Key Points: 
  • EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced a new collaboration with the United Nations-Guided Global Initiative on Ageing (GIA) to provide a training course on critical skills for family caregivers.
  • “As the world’s population of ageing adults continues to significantly increase, the importance of caregivers has become even more critical to address their health needs,” said Ambassador Luis Gallegos, Chairman of the Global Initiative on Ageing.
  • The modules provide support for a broad range of caregivers - whether they care for patients impacted by cancer, multiple sclerosis or other diseases and chronic conditions.
  • “At EMD Serono, we recognize the invaluable role family caregivers play, not only in the lives of patients, but across the entire healthcare ecosystem.

EMD Serono Launches New Collaboration with United Nations’ Global Initiative on Ageing to Support Caregivers

Retrieved on: 
Thursday, October 5, 2023

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced a new collaboration with the United Nations’ Global Initiative on Ageing (GIA) to provide a training course on critical skills for family caregivers.

Key Points: 
  • EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced a new collaboration with the United Nations’ Global Initiative on Ageing (GIA) to provide a training course on critical skills for family caregivers.
  • “As the world’s population of ageing adults continues to significantly increase, the importance of caregivers has become even more critical to address their health needs,” said Ambassador Luis Gallegos, Chairman of the Global Initiative on Ageing.
  • The modules provide support for a broad range of caregivers - whether they care for patients impacted by cancer, multiple sclerosis or other diseases and chronic conditions.
  • “At EMD Serono, we recognize the invaluable role family caregivers play, not only in the lives of patients, but across the entire healthcare ecosystem.

The Global In Vitro Toxicology Testing Market is Poised for Exponential Growth and is Expected to Reach USD 64,094.9 Million by 2030 | Infinium Global Research

Retrieved on: 
Thursday, October 12, 2023

The in vitro toxicology testing market has been experiencing remarkable growth in recent years.

Key Points: 
  • The in vitro toxicology testing market has been experiencing remarkable growth in recent years.
  • The increasing demand for toxicology testing products propels the growth of the in vitro toxicology testing market.
  • Nonetheless, technological advancements in in vitro toxicology testing products create opportunities for companies operating in the market.
  • The global in vitro toxicology testing market is primed for substantial growth, driven by increasing government support, rising demand for toxicology testing products, and technological advancements.

Growing Sustainability Initiatives and Mergers Define Recent Trends in the Global Persulfates Market

Retrieved on: 
Monday, October 9, 2023

The global Persulfates market is poised for significant growth, driven by increasing demand from diverse end-use industries.

Key Points: 
  • The global Persulfates market is poised for significant growth, driven by increasing demand from diverse end-use industries.
  • The Persulfates market has witnessed consistent growth in recent years, primarily fueled by the escalating demand from industries such as electronics, water treatment, and cosmetics.
  • Sustainability has emerged as a significant focus in the Persulfates market in recent years.
  • This report encompasses the global Persulfates market and is segmented into the following categories: